Lifestyle Interventions for Heart Disease Risk Reduction
This trial will improve cardiovascular risk stratification, identify disparities in risk based on race and location, and evaluate mechanisms for population differences in risk. A multidisciplinary community-based intervention program will be implemented to decrease cardiovascular risk in high-risk populations.
Popular Filters
Trials for Single Ventricle Heart Disease Patients
Device
Carillon Device for Heart Failure with Mitral Regurgitation
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
ASD Occluder
reSept ASD Occluder for Atrial Septal Defect
This trial is testing the safety and effectiveness of the reSept ASD Occluder, a device that closes a specific type of heart hole. It targets patients with secundum atrial septal defect and works by sealing the hole like a patch.
Trials for SVHD Patients
Device
Carillon Device for Heart Failure with Mitral Regurgitation
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
ASD Occluder
reSept ASD Occluder for Atrial Septal Defect
This trial is testing the safety and effectiveness of the reSept ASD Occluder, a device that closes a specific type of heart hole. It targets patients with secundum atrial septal defect and works by sealing the hole like a patch.
Phase 3 Trials
Monoclonal Antibodies
Lerodalcibep for High Cholesterol
This trial involves regular injections of LIB003 for patients with cardiovascular disease or at high risk, including those with certain genetic conditions. The goal is to lower their bad cholesterol levels to help prevent heart disease.
Trials With No Placebo
Stem Cell Therapy
iPSC-CL for Congenital Heart Disease
This trial aims to test if lab-grown heart cells, made from stem cells, are safe and feasible to use to treat people with congenital heart disease. Participants must agree to testing and monitoring before and after product administration, and lifelong follow-up.
3D Heart Models for Congenital Heart Disease
This trial studies the use of 3D printed heart models to help plan surgeries for children with complex congenital heart disease and heart failure. The models aim to give doctors a better understanding of the patient's heart, potentially leading to safer and more effective surgeries. 3D printing technology is emerging as a potential new tool for planning medical interventions, particularly in congenital heart disease settings.
View More Related Trials
Frequently Asked Questions
Introduction to heart disease
What are the top hospitals conducting heart disease research?
When it comes to advancing medical knowledge and finding innovative solutions for heart disease, several hospitals are at the forefront of groundbreaking clinical trials. In Rochester, Minnesota, the Mayo Clinic leads the charge with four active trials focused on heart disease. This renowned institution has a long-standing reputation for excellence in healthcare and research. Similarly, the University of Ottawa Heart Institute in Canada is dedicated to combating heart disease through three ongoing clinical trials. Located in Ottawa's capital city, this institute brings together leading experts in cardiology who strive to improve patient outcomes.
In Edmonton, Alberta, the University of Alberta is actively contributing to our understanding and treatment of heart disease through three current clinical trials. Situated amidst Canada's stunning natural beauty, this hospital combines cutting-edge research with compassionate care. Additionally making strides in heart disease research is Banner University Medical Center in Phoenix where two ongoing clinical trials are underway. This center boasts state-of-the-art facilities and a multidisciplinary approach that ensures comprehensive patient care.
Lastly but certainly not leastly; UC Health Northern Colorado/Medical Center of the Rockies located Loveland has also committed itself towards furthering our knowledge about complications related to heart diseases by conducting two active experiments as they do their part while having no previous records regarding such undertakings before following its pledge towards pioneering efforts providing ample opportunities treating cardiovascular disorders.
These esteemed hospitals represent beacons of hope for those affected by heart disease worldwide—dedicated teams working tirelessly to find answers and develop better treatments. By participating in these innovative clinical trials, patients play an integral role in shaping future advancements that have far-reaching implications for countless lives impacted by this prevalent condition
Which are the best cities for heart disease clinical trials?
In the realm of heart disease clinical trials, several cities emerge as prominent hubs for research. New york, New York takes the lead with 10 active studies exploring a diverse range of treatments such as SAPIEN 3 THV and the utilization of a 3D model of the heart. Following closely behind are Rochester, Minnesota and Los Angeles, California, both with 6 ongoing trials investigating interventions like Edwards SAPIEN 3/SAPIEN 3 Ultra THV. Boston, Massachusetts and Chicago, Illinois also contribute to the field with their respective sets of active trials focused on advancements in heart disease management. These cities serve as invaluable centers for innovative research that holds promise for improving outcomes in individuals affected by heart disease.
Which are the top treatments for heart disease being explored in clinical trials?
Heart disease research is advancing rapidly, with several innovative treatments taking center stage in clinical trials. Leading the charge are three standout contenders:
- Daratumumab: This powerful drug has shown great promise in six active trials for heart disease, demonstrating its potential to revolutionize treatment options.
- Belantamab mafodotin: With four ongoing trials, belantamab mafodotin is making waves as a potential breakthrough therapy for heart disease.
- Lenalidomide: A well-established player in the field of medicine, lenalidomide continues to shine with three active trials dedicated to exploring its efficacy against heart disease. These cutting-edge treatments offer hope for patients and signify significant progress on the path toward improved cardiac care.
What are the most recent clinical trials for heart disease?
Exciting developments in the field of heart disease research have emerged through recent clinical trials. One such trial involves CagriSema, a potential treatment for heart disease that has reached Phase 3 of testing. Additionally, researchers are exploring the efficacy and safety of a new therapeutic approach known as "Treated" in Phase 1 trials. Another study focuses on the de-adoption of beta-blockers as a treatment option for heart disease in Phase 4 investigations. Furthermore, Sulfur Hexafluoride Lipid Type A Microspheres Suspension and NNC6019-0001 show promise in their respective phases, bolstering hopes for improved management and outcomes for individuals living with heart disease.
What heart disease clinical trials were recently completed?
Several recent clinical trials focused on advancements in treating heart disease have reached completion, showcasing the commitment of researchers to improving cardiovascular health. Notably, a trial sponsored by Boston Scientific Corporation investigated the effectiveness of a novel cardiac device and concluded recently. Additionally, a study conducted by the National Heart, Lung, and Blood Institute examined the impact of an innovative medication on reducing cardiovascular risk factors and was finalized this year. These accomplished trials represent significant strides in our understanding and treatment options for heart disease patients.